-
Company Profile
![]()
NH Foods Ltd – Company Profile
NH Foods Ltd (NH Foods) is a manufacturer and marketer of food products. The company offers cooked foods, fresh meat and processed meat such as hams and sausages, pre-prepared foods, pork, chicken, and other meat products, retort-packed food, processed marine products and dairy products. NH Foods through Nipponham is involved in farming and breeding of livestocks, such as cattle, hogs, and poultry. The company markets food under Chuka Meisai, Ishigama Kobo and Schau Essen brand names. It sells its products...
Add to Basket -
![]()
NHS UK – Hornchurch Health Centre – Greater London
Equip yourself with the essential tools needed to make informed and profitable decisions with our NHS UK – Hornchurch Health Centre – Greater London report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:Dive deep...
-
Product Insights
New![]()
Optical Coherence Tomography (OCT) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Optical Coherence Tomography (OCT) equipment allows for the imaging and measurement of retinal thickness. GlobalData's Medical Devices sector report, “Optical Coherence Tomography (OCT) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the Optical Coherence Tomography (OCT) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Optical Coherence Tomography (OCT) report provides key...
-
Thematic Analysis
New![]()
Artificial Intelligence (AI) in Clinical Practice – Patient Perspective – Thematic Intelligence
Artificial Intelligence (AI) in Clinical Practice Thematic Report Overview According to the survey, younger patients (18-55 years old) are more likely to be familiar with AI than the older (56+ years) patients as they have been exposed to technologies such as computers and smart devices from a younger age and thus, may be more comfortable with innovation use. Following this trend, patients familiar with AI selected more advantages associated with AI implementation in clinical practice compared to those unfamiliar with this technology. This...
-
Product Insights
![]()
GBI/ NH Hoteles – NH Hotel Hamburg Zentrum Development – Hamburg
Equip yourself with the essential tools needed to make informed and profitable decisions with our GBI/ NH Hoteles - NH Hotel Hamburg Zentrum Development - Hamburg report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Colorectal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Mesenchymal Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Mesenchymal Tumor Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Penile Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Penile CancerDrug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Rectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Rectal CancerDrug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Esophageal Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Esophageal TumorDrug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Small Intestine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Small Intestine CancerDrug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Epithelial Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Epithelial TumorDrug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of metastatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Vulvar Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Vulvar Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Non-Small Cell Lung Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Oropharyngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Oropharyngeal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Kidney Cancer (Renal Cell Cancer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Kidney Cancer (Renal Cell Cancer) Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Urinary Tract Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Urinary Tract Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Vaginal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Vaginal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Cervical Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Cervical Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.